Peplin Inc. (Peplin) is a development-stage pharmaceutical company. In November 2009, Peplin was acquired by LEO Pharma, a Denmark-based pharmaceutical company. Peplin is engaged in researching, advancing and commercializing of innovative drugs in medical dermatology. The company is developing anti-cancer drug, namely PEP005 which is derived from Euphobia peplus, a plant referrd to as radium weed or petty spurge, for the following indications of actinic (solar) keratosis (AK) and basal cell carcinoma (BCC). PEP005 Gel is useful as a topical, field-directed therapy for AK lesions on both head (face and scalp) and non-head (trunk and extremities) locations. It is in evaluating the anti-cancer properties of natural products sourced from non-indigenous plants of the genus euphorbiaceae. Peplin is operating a manufacturing facility located in Southport, Queensland, Australia for API production of its owned proprietary, lead compound PEP005 (ingenol mebutate). Peplin is headquartered at Emeryville in California, the US.The operating loss of the company was USD 43.29 million during the fiscal year 2009, as compared to an operating loss of USD 27.67 million during 2008. The net loss of the company was USD 43.87 million during the fiscal year 2009, as compared to a net loss of USD 25.96 million during 2008.